Organic Active Ingredients TRIZ Cases

A distinct PPARγ agonist binding mode cuts proteinuria and glomerular injury while avoiding the weight gain and edema seen with older agents.

A porous implant scaffold enables tissue ingrowth before insulin-expressing cell infusion, improving vascularization and reducing immune damage.

Copper-mediated hydrazone cyclization improves 2-aryl triazole selectivity, raising yield while cutting waste and separation cost.

Recombinant CD20-presenting antigen cells activate T cells to selectively kill B cell lymphoma cells where chemo and radiation lack targeting.

Adenosine deaminase base editing corrects ABCA4 pathogenic variants to restore gene function and help slow progressive vision loss.

A higher anti-CD19 antibody dose extends dosing intervals, reducing hospital visits and infection exposure while maintaining efficacy.

A Lewis acid and sulfuric acid-water sequence improves viloxazine intermediate purity while controlling exotherms for industrial synthesis.

Targeting NASP RNA splicing with splice-switching oligonucleotides reveals therapeutic vulnerability in high-risk meningioma cells.

Encapsulating self-amplifying IL-12 replicon RNA in lipid nanoparticles drives local immunogenic cell death and systemic tumor immunity.

Crystalline PC945 forms improve stability, micronization, and lung-site bioavailability for inhaled treatment of invasive fungal infections.

Binding two distinct FRα epitopes improves ADC delivery and tumor cell killing in high FRα-expressing cancers, including ovarian cancer.

A flexible six-month paliperidone palmitate regimen uses a defined dosing window and re-initiation steps to improve adherence and reduce relapse risk.

Using S-1-propenylcysteine to raise blood eNAMPT and NAD+ offers a route to sirtuin activation and senescent cell suppression.

A dual-pathway blend of resistant starch, amino acids, vitamins, and electrolytes speeds rehydration while extending hydration effect.

Novel benzisoxazole sulfonamide derivatives improve KAT inhibition and MYST family selectivity to help regulate abnormal cell growth.

Lipid-based pleconaril formulations improve sepsis treatment by boosting bioavailability and targeted delivery while limiting systemic side effects.

Twice-daily Compound 1 dosing sustains plasma levels and brain penetration needed to treat mIDH1 cancers such as glioma and AML.

Focused CBC derivative compounds expand therapeutic use across cancer, neurodegenerative, psychiatric, and pain indications with controlled dosing.

A layered nanoparticle uses pH-triggered release and magnetic targeting to improve bioavailability while limiting off-target senolytic toxicity.

Using kojibiose-based oligosaccharides, this case shows how to raise Parabacteroides and Bifidobacterium without direct probiotic delivery.

Selective topical mTOR inhibitors improve skin penetration and stability to treat skin disorders with lower systemic side effects.

Direct nasal delivery of apigenin with a linear peptide inhibitor targets mitochondrial dysfunction in neural cells to reduce oxidative stress and cell death.

Fatty acid precursors stimulate MSCs to produce pro-resolving mediators that reduce osteoarthritis inflammation and support joint tissue regeneration.

A tear-compatible JAK inhibitor eye drop improves ocular bioavailability and treats non-infectious uveitis with fewer side effects.

A circularizing domain masks oligonucleotide ends to improve nuclease stability, limit PRR-driven immune activation, and enable intracellular release.

Chelating green tea bioactives with iron creates a powdered extract that eases gastrointestinal symptoms while avoiding common side effects.

PP2A-modulating aminotetrahydropyran derivatives suppress MYC signaling and help restore chemotherapy sensitivity in resistant cancers.

Substituted heterocycles tune KRAS inhibition, solubility, and normal-cell cytotoxicity to support cancer treatment.

MAS receptor agonists stimulate mitophagy and mitochondrial turnover to address diseases linked to inadequate mitochondrial renewal.

Mild extracellular potassium elevation boosts flecainide action to improve AF conversion, shorten termination time, and lower proarrhythmia risk.

A selective FGFR3 inhibitor targets FGFR3-altered solid tumors to limit off-target toxicity and address resistance seen with pan-FGFR drugs.

A non-aqueous 1.8% lidocaine patch uses a composite adhesive matrix to limit crystallization, improve skin permeation, and sustain release.

Pyrrolopyridine JAK1/JAK3 inhibitors are tuned for topical or oral delivery to preserve efficacy while limiting systemic toxicities.

A closed automated CAR T workflow uses activating lentiviral vectors to raise transfection efficiency, reduce contamination risk, and support infusion.

Biased Kv7 activators raise Kv7.2/7.3 current while limiting Kv7.4 activity, helping reduce concentration-linked side effects.

Tocopherol-modified oligonucleotides form a dense anionic shell that keeps small liposomes stable and aggregation-resistant for gene delivery.

Biomarker profiling links multiple myeloma progression and chemoresistance risk to gene-expression targets, enabling more personalized treatment.

Cell-targeted oligonucleotide conjugates use nucleotide and linkage modifications to drive exon skipping or inclusion and restore functional proteins.

Blocking PD-1 restores T-cell activity to cut HBV particle load and improve symptoms when standard HBV treatments fail to clear infection.

Combining cellular kinase inhibitors with IAP-targeting formula I compounds improves proliferative disease treatment while maintaining non-toxic properties.

BDDE-crosslinked hyaluronic acid gel evenly disperses triamcinolone to improve stability and extend osteoarthritis relief.

Modified ABE8 with guide RNA targeting corrects HBB SNPs linked to sickle cell disease, achieving over 60-70% editing efficiency.

New MYST family KAT inhibitor compounds use scaffold and substituent tuning to improve selectivity while maintaining anticancer activity.

Targeted endothelin injury in primate basal ganglia and thalamus creates a reproducible chronic stroke model for evaluating NeuroD1 therapy.

Short-chain polyhomoarginine improves corneal penetration and bioavailability while rapidly inhibiting fungal and bacterial infections.

Vision sensors and AI quantify exposure, viewing, and attention around outdoor ads in real time, improving measurement accuracy for campaign optimization.

Glycosylated hydroxytryptamine compounds modulate serotonin receptors to deliver alcohol-like recreational effects without hangovers or liver damage.

A dual-matrix tablet uses hydrophilic and insoluble release agents to lower peak PDE10 plasma levels while sustaining therapeutic exposure.

A fixed-ratio combination with 5-amino-2,3-dihydro-1,4-phthalazinedione boosts anti-inflammatory efficacy while lowering fumaric ester dosage and side effects.

Combining chidamide, sintilimab, and IBI305 improves MSS/MSI-L colorectal cancer response rates while prolonging progression-free survival.

Novel piperidinedione CRBN binders improve PROTAC target protein degradation, supporting anticancer and immunomodulatory use.

A 1-cyano nucleoside scaffold is tuned with substituent changes to treat multiple viral families while maintaining therapeutic efficacy.

Specific amino acid ratios keep IL-6 within physiological levels to reduce skin inflammation while preserving immune response and collagen-elastin synthesis.

Selective TYK2 compounds treat autoimmune, inflammatory, and proliferative disorders while minimizing JAK2 off-target side effects.

Natural pectin from fruit pulp forms nano/microcapsules that stabilize bioactives, improve taste, and enable gradual digestive release.

Formula (I) pyrrolo and pyrazolopyrimidine compounds selectively inhibit USP7 to expand treatment options while improving efficacy and safety.

Chlorotoxin-based CAR γδT cells improve glioma selectivity while limiting off-target tissue effects and retaining activity during chemotherapy.

Modular TYK2 inhibitor scaffolds improve kinase selectivity, helping treat autoimmune and inflammatory disorders while sparing JAK2.

Macrocyclic FKBP51 binders use topology and substituent tuning to improve selectivity and affinity without excessive molecular weight or lipophilicity.

Engineered zinc finger transcription factors repress MAPT expression to lower tau levels and slow tau aggregation in Alzheimer's-related tauopathy.

A non-cleavable PEG lipid uses pH-triggered positive charge to form stable bioactive particles and improve target-cell delivery.

Heating and curing the fabric before adding the active-substance binder reduces volatilization and improves immediate flavor release.

A pH 3.0-3.6 epinephrine liquid formulation uses organic acid buffering to extend room-temperature shelf life while limiting impurities.

Engineered gut-colonizing microbes produce L-DOPA continuously, helping reduce dyskinesia risk while sustaining Parkinson's symptom relief.

Tocopheryl phosphates with long-chain lipids improve oral cannabinoid solubilization and absorption, raising bioavailability, cMax, and AUC.

A multi-solvent lipoxygenase inhibitor formulation enables 30 mg/mL or higher IV dosing while overcoming solubility limits.

mTOR and antiviral restriction factor inhibitors help pseudotyped viral vectors overcome cellular barriers and improve exogenous agent delivery.

A polymer-based amorphous solid dispersion improves solubility, limits food effect, and maintains oral exposure for BNC210 tablets.

Controlled extraction of fish-testes DNA tunes fragment size for oral use against osteoarthritis, bone resorption, and oxidative stress.

Heterobifunctional PROTAC compounds recruit E3 ligase to ubiquitinate and degrade BTK, enabling stronger control of BTK-driven cancers.

pH adjustment and disodium edetate keep injectable fosnetupitant soluble, stable, and less prone to degradation or injection site reactions.

Specific Formula (I) substituent patterns improve JAK1 selectivity while limiting other JAK kinase activity and related side effects.

Multiple dispense streams and controlled conditions prevent freezing and agglomeration during pharmaceutical cryogranulation, improving pellet yield.

Blocking oxidation of OTUB1 Cys23/Cys204 disrupts system xC-, depletes GSH, and sensitizes cancer cells to chemo and checkpoint therapy.